Literature DB >> 2795434

Optimum schedule of selenium administration to reduce lethal and renal toxicities of cis-diamminedichloroplatinum in mice.

M Satoh1, A Naganuma, N Imura.   

Abstract

The optimum conditions of selenium administration to reduce the side effects of a single dose of cis-diamminedichloroplatinum (cis-DDP) in mice were examined. The best effects against lethal toxicity of cis-DDP was obtained when sodium selenite was administered subcutaneously (s.c.) to mice simultaneously with s.c. injected cis-DDP at a molar ratio of 1 to 3.5 (sodium selenite to cis-DDP) on the first day and the same amount of selenite was given daily for four subsequent days. This coadministration of selenite completely depressed not only lethal toxicity of cis-DDP but also its renal toxicity (indicated by increased blood urea nitrogen values) and intestinal toxicity (indicated by the incidence of diarrhea) which were usually observed in the mice treated with cis-DDP alone. Furthermore, coadministration of selenite did not compromise the antitumor activity of cis-DDP against several transplantable tumors in mice. Therefore, the administration schedule of selenite with cis-DDP described above may be useful for cancer chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2795434     DOI: 10.1248/bpb1978.12.246

Source DB:  PubMed          Journal:  J Pharmacobiodyn        ISSN: 0386-846X


  8 in total

Review 1.  Physiological and nutritional importance of selenium.

Authors:  J Nève
Journal:  Experientia       Date:  1991-02-15

2.  Effect of coadministration of selenite on the toxicity and antitumor activity of cis-diamminedichloroplatinum (II) given repeatedly to mice.

Authors:  M Satoh; A Naganuma; N Imura
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 3.  WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.

Authors:  M Treskes; W J van der Vijgh
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

4.  An XRF study of trace elements accumulation in kidneys of tumor-bearing mice after treatment with cis-DDP with and without selenite and selenocistamine.

Authors:  C Shenberg; M Boazi; J Cohen; A Klein; M Kojler; A Nyska
Journal:  Biol Trace Elem Res       Date:  1994-02       Impact factor: 3.738

5.  Effect of bismuth nitrate given in combination with cis-diamminedichloroplatinum(II) on the antitumor activity and renal toxicity of the latter in nude mice inoculated with human bladder tumor.

Authors:  Y Kondo; M Satoh; N Imura; M Akimoto
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

6.  Effect of pharmacologic doses of zinc on the therapeutic index of brain tumor chemotherapy with carmustine.

Authors:  N Roosen; F Doz; K L Yeomans; D V Dougherty; M L Rosenblum
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Se-methylselenocysteine offers selective protection against toxicity and potentiates the antitumour activity of anticancer drugs in preclinical animal models.

Authors:  S Cao; F A Durrani; K Tóth; Y M Rustum
Journal:  Br J Cancer       Date:  2014-03-11       Impact factor: 7.640

Review 8.  Cisplatin-Induced Nephrotoxicity; Protective Supplements and Gender Differences

Authors:  Mehdi Nematbakhsh; Zahra Pezeshki; Fatemeh Eshraghi Jazi; Bahar Mazaheri; Maryam Moeini; Tahereh Safari; Fariba Azarkish; Fatemeh Moslemi; Maryam Maleki; Alireza Rezaei; Shadan Saberi; Aghdas Dehghani; Maryam Malek; Azam Mansouri; Marzieh Ghasemi; Farzaneh Zeinali; Zohreh Zamani; Mitra Navidi; Sima Jilanchi; Soheyla Shirdavani; Farzaneh Ashrafi
Journal:  Asian Pac J Cancer Prev       Date:  2017-02-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.